Esomeprazole sodium

Esomeprazole sodium (CAS 161796-78-7), also referenced in clinical and procurement contexts as Nexium IV, is the sodium salt form of the S-enantiomer of omeprazole. It was developed for intravenous pharmaceutical applications. It functions as a proton pump inhibitor (PPI) active pharmaceutical ingredient (API), suppressing gastric acid secretion for therapeutic formulation use. The primary application is in the manufacture of injectable formulations.

These formulations are used for hospital and clinical settings where rapid acid suppression is required when oral administration is not feasible. It is used by pharmaceutical manufacturers producing IV solutions for various conditions. Common uses include gastroesophageal reflux disease and stress ulcer prophylaxis in critical care patients. Formulators also source it as the API for lyophilized powder-for-injection presentations for aqueous parenteral systems.

The sodium salt form supports specific solubility requirements in these systems. Generic drug manufacturers targeting regulated markets rely on it as the reference-aligned active for biosimilar and generic IV PPI product development. Esomeprazole sodium is supplied as a white to off-white lyophilized powder or crystalline solid. It is available in pharmaceutical-grade specifications aligned with USP and Ph. Eur. monograph requirements.

Sourcing is typically in small-to-medium quantities suited to API procurement workflows. Documentation packages are provided to support regulatory submissions and ensure compliance with international pharmaceutical standards.